Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Technical Presentation (March 2018)

19 slides from Biohaven Pharmaceutical's technical presentation, Mar 26, 2018

  1. Slide 1: Forward-Looking Statement

    Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop rimegepant, including the timing for regulatory submissions, and the safety and efficacy of rimegepant. These statements involve substantial known and unknown risks, unce

  2. Slide 2: Rimegepant 75 mg Phase 3 Top Line Summary from Study 301 and Study 302: Acute Treatment of Migraine

    Rimegepant 75 mg Phase 3 Top Line Summary from Study 301 and Study 302: Acute Treatment of Migraine ©2018 Biohaven

  3. Slide 3: Overview: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials

    Overview: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials Results statistically signific

  4. Slide 4: Design for Pivotal Phase 3 Trials of Rimegepant: Studies 301 and 302

    Design for Pivotal Phase 3 Trials of Rimegepant: Studies 301 and 302 Screening Randomization Phase End of Study Visit Up to 45 days 3-28 days Within 7 days of Dosing (+2 days) Rimegepant 75 mg Placebo 1:1 Randomization End of Study Visit Study 301 and Study 302 had identical study designs: 301: 1162

  5. Slide 5: Descriptive Summary of Pooled Study Demographics

    Descriptive Summary of Pooled Study Demographics1: Trials Representative of Typical Migraine Patient Population Patient Demographics and Migraine History Female > Male (~85% F; 15% M) Average age = ~40 years old Diverse patient population across the U.S. Mean number of historical moderate to severe

  6. Slide 6: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials

    Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant 2 hour Endpoint Rimegepant n=537 Placebo n=535 p-value Pain Freedom 19.6% 12.0% < 0.001 Freedom from MBS1 37.6% 25.2% < 0.0001 Study 302 2 hour Endpoint Rimegepant n=543 Placebo n=541 p-value P

  7. Slide 7: Pain Freedom: Early Separation and Continued Improvement (Study 302)

    Pain Freedom: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 302) Kaplan-Meier Curve of Time to Pain Freedom up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medica

  8. Slide 8: Pain Freedom: Increasing Benefit Over Time (Study 302)

    Pain Freedom: Increasing Benefit Over Time Single Dose of Rimegepant, No Rescue Meds (Study 302) ©2018 Biohaven Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medication or were lost to follow-up during the specified interval % of Patients Pain

  9. Slide 9: Pain Relief: Early Separation and Continued Improvement (Study 302)

    Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 302) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain relief; subjects were censored (not included) who took rescue medicatio

  10. Slide 10: Pooled Liver Function Test (LFT) Profile: Rimegepant Similar to Placebo

    Pooled Liver Function Test (LFT) Profile: Rimegepant was Similar to Placebo in Both Studies ALT or AST Rimegepant n=1089 Placebo n=1092 > ULN1 24 (2.2%) 32 (2.9%) > 3x ULN 1 (0.1%) 1 (0.1%) > 5x ULN 0 0 > 10x ULN 0 0 > 20x ULN 0 0 *No bilirubin elevations >2x ULN across both Studies 301 and 302 1ULN

  11. Slide 11: Rimegepant was Well Tolerated: No Single Adverse Event Occurring >2%

    Rimegepant was Well Tolerated: No Single Adverse Event Occurring > 2% Pooled Adverse Event (AE) Safety Data From Study 301 and Study 302 Percent (number) of Patients Reporting an Adverse Event within 48 Hours Post-Dose > 1% Incidence Adverse Event Placebo n=1092 Rimegepant n=1089 > 1 On-Study AE* 12

  12. Slide 12: Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints

    Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials Results are statistically signi

  13. Slide 13: Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints

    mmary: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant * Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials * Results are statistically sig

  14. Slide 14: Backup Slides

    Backup Slides ©2018 Biohaven

  15. Slide 15: Pain Freedom: Early Separation and Continued Improvement (Study 301)

    Pain Freedom: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Freedom up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medica

  16. Slide 16: Pain Freedom: Increasing Benefit Over Time (Study 301)

    Pain Freedom: Increasing Benefit Over Time Single Dose of Rimegepant, No Rescue Meds (Study 301) ©2018 Biohaven Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medication or were lost to follow-up during the specified interval Pain Freedom 2-8 H

  17. Slide 17: Pain Relief: Early Separation and Continued Improvement (Study 301)

    Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain relief; subjects were censored (not included) who took rescue medicatio

  18. Slide 18: Pain Relief: Early Separation and Continued Improvement (Study 301)

    Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose 1.0 TRnegenant eS) Study 301 | 0.9 0.8 0.7 0.6 0.5 0.4 0.3 Probability of Pain Relief 0.2 0.1 Single Dose of Ri

  19. Slide 19: BHVN

    BHVN LISTED 12018 Biohaven

Biohaven Pharmaceutical Holding — Technical Presentation (March 2018) on 6ix